Combination of gabapentin and ramosetron for the prevention of postoperative nausea and vomiting after gynecologic laparoscopic surgery: a prospective randomized comparative study

Table 1 Patients’ characteristics and clinical data

Characteristic	Group G (n = 40)	Group R (n = 44)	Group GR (n = 40)	P value (overall)
Age (year)	44.5 ± 11.1	44.2 ± 9.7	43.2 ± 9.2	0.831
Height (cm)	157.3 ± 5.4	158.3 ± 6.7	157.8 ± 4.9	0.753
Weight (kg)	60.5 ± 9.7	59.7 ± 11.3	61.9 ± 10.1	0.620
PONV history	4 (10.0)	3 (6.8)	2 (5.0)	0.683
Motion sickness history	3 (7.5)	8 (18.2)	6 (15.0)	0.349
Nonsmoking status	37 (92.5)	39 (88.6)	36 (90.0)	0.833
Apfel’s risk score for PONV				0.465
3	5 (12.5)	10 (22.7)	8 (20.0)
4	35 (87.5)	34 (77.3)	32 (80.0)
Type of laparoscopic surgery				0.414
Total hysterectomy^a	13 (32.5)	21 (47.7)	21 (52.5)
Ovarian cystectomy	17 (42.5)	10 (22.7)	9 (22.5)
Myomectomy	6 (15.0)	7 (15.9)	5 (12.5)
Salpingo-oophorectomy	4 (10.0)	6 (13.6)	5 (12.5)
Duration of surgery (min)	102.0 ± 58.8	101.1 ± 53.1	101.3 ± 44.0	0.997
Duration of anesthesia (min)	146.1 ± 61.0	141.9 ± 58.1	136.1 ± 46.1	0.721
ASA class I/II	24/16	25/19	21/19	0.794

Data presented as mean ± SD or n (%) of patients
Data were analyzed using ANOVA (continuous variables) or χ ² test (incidence variables)
Group G, patients received oral gabapentin 300 mg 1 h before induction of anesthesia; Group R, patients received intravenous ramosetron 0.3 mg at the end of surgery; Group GR, patients received oral gabapentin 300 mg 1 h before induction of anesthesia and intravenous ramosetron 0.3 mg at the end of surgery; PONV postoperative nausea and vomiting; Apfel’s risk score consists of four predictors: nonsmoking, female, history of motion sickness and/or PONV, postoperative opioid; ASA American Society of Anesthesiologists’ physical status
^a In some patients, salpingo-oophorectomy was perforemed together

ISSN: 1471-2253